Wyeth is transforming its R&D pipeline in order to plug its looming patent expiry hole and to remain as a dominant force among big pharma. With its filing of five NDAs in 2006, Wyeth has the most exhilarating late-stage new product pipelines that place the company in a strong position to take the challenges from smaller biotech and big pharma alike. Based on Wyeth’s performance investors can possibly lift the lid on their cautious assessment of the company.